Boundless Bio, Inc.

Boundless Bio, Inc. is a clinical-stage oncology biotechnology company focused on cancers driven by oncogene amplification. Its core scientific thesis is that extrachromosomal DNA, or ecDNA, is a root cause of oncogene amplification in a meaningful subset of cancer patients, and the company is building therapies to target that biology. The company has not yet commercialized any products and is still in the development phase, with its efforts centered on discovering and advancing ecDNA-directed therapeutic candidates, or ecDTx. As of early 2026, Boundless Bio has narrowed its research and development focus to BBI-940 and is pursuing a capital-efficient path while it advances clinical development.

8.74

8.74

— Boundless Bio, Inc.
%
ecDNA-directed therapeutic candidates0% Drug candidates designed to treat oncogene amplified tumors by targeting extrachromosomal DNA biology.
Clinical development programs0% Ongoing preclinical and clinical studies intended to generate safety, efficacy, and dosing data for lead assets.
Discovery platform0% The Spyglass platform used to interrogate ecDNA biology and identify new therapeutic opportunities.
Diagnostic development0% Development of an ecDNA diagnostic test to support patient identification and translational research.
Research collaboration and future commercialization0% Potential partnering, licensing, and commercialization activities if candidates reach approval.

Boundless Bio does not currently sell products or serve commercial customers, so its near-term counterparties are...

  • Patients with oncogene amplified tumorsprimary

    The ultimate end users of ecDTx, targeted at cancers where ecDNA drives oncogene amplification and existing therapies often underperform.

  • Oncology physicians and cancer centersprimary

    Would prescribe and administer any approved therapy, making clinical differentiation and biomarker strategy important.

  • Clinical trial investigators and sitessecondary

    Enroll patients and generate the clinical evidence needed to advance lead programs through development.

  • Contract research organizationssecondary

    Provide outsourced preclinical and clinical research services that support the company’s development pipeline.

  • Third-party manufacturers and supply chain vendorssecondary

    Manufacture, package, label, store, and distribute ecDTx for trials and eventual commercialization.

Boundless Bio is headquartered in the United States and currently conducts its business primarily through U.S...

  • •Headquartered in the United States
  • •Current operations are centered on U.S. research and development
  • •No owned manufacturing footprint; relies on external suppliers
  • •Future commercialization is expected to begin in the United States
  • •Potential expansion to other major markets would depend on approvals and partners

Boundless Bio is prioritizing a narrower pipeline after portfolio review, with research and development now focused on...

01
Concentrate resources on BBI-940short-term

A narrower pipeline improves capital efficiency and increases the chance of meaningful clinical progress on the most advanced program.

02
Advance ecDNA-directed therapeutics through clinical developmentmedium-term

Clinical proof-of-concept is required before any regulatory approval, partnering leverage, or commercial revenue can emerge.

03
Preserve liquidity and access to capitalshort-term

The company has no product revenue and must fund long development timelines through external financing.

04
Build future commercialization optionalitylong-term

If a candidate is approved, the company will need either internal commercial capabilities or a partner to reach patients.

Boundless Bio faces the classic risks of a clinical-stage biotech company: no product revenue, long development...

high

Need for substantial additional capital

The company has no product revenue and must finance long-duration R&D and clinical programs through external funding.

Scope
Could force delays, reductions, or termination of ecDTx programs if capital is unavailable.
Materiality
high
high

Clinical development failure

Lead candidates may not demonstrate sufficient safety or efficacy to advance to approval.

Scope
Would impair the company’s ability to create value from its ecDNA platform.
Materiality
high
high

Regulatory and approval uncertainty

Biopharmaceutical products require extensive testing and regulatory review before commercialization.

Scope
Approval may never occur, or may require additional studies and time.
Materiality
high
medium

Third-party manufacturing and supply chain dependence

The company does not own manufacturing facilities and relies on external vendors for clinical and future commercial supply.

Scope
Delays or quality issues could disrupt trials and future launch readiness.
Materiality
medium
medium

Competitive pressure in oncology

Larger biopharma and biotech companies may develop competing precision oncology programs with greater resources.

Scope
Could reduce partnering leverage, trial enrollment, and eventual market opportunity.
Materiality
medium
Accrued research and development expenses
Can shift expenses between quarters and affect comparability
Stock-based compensation
Affects reported operating loss without immediate cash outflow
Prepaid R&D services
Can create timing differences in expense recognition and working capital
Going-concern and liquidity assumptions
Liquidity assumptions influence disclosures and investor assessment of runway

BridgeBio Oncology Therapeutics, Inc.

BBOT · Pharmaceutical Preparations

MUSTANG BIO, INC.

MBIO · Pharmaceutical Preparations

Theriva Biologics, Inc.

TOVX · Pharmaceutical Preparations

Black Diamond Therapeutics, Inc.

BDTX · Biological Products, (No Diagnostic Substances)

MACROGENICS INC

MGNX · Pharmaceutical Preparations

Bionano Genomics, Inc.

BNGO · Laboratory Analytical Instruments

: 11/08/2026